chromosome 1 open reading frame 185Genealiases: []
Q-omics provides the consensus-scored C1orf185 profile across patient tissues and cancer cell-line models. C1orf185 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C1orf185 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, C1orf185 RNA expression shows 6,703 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, BRCA, and STAD as cancer lineages where C1orf185 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf185 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf185 survival associations across molecular data types. C1orf185 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf185 RNA expression–survival associations across cancer types. High C1orf185 expression shows unfavorable associations in UVM, DLBC, MESO, LGG and LUAD, but favorable associations in ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for C1orf185 RNA expression.
This table summarizes C1orf185 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for C1orf185. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf185 shows lower tumor expression in BRCA and KICH and higher tumor expression in KIRC, PRAD and LUAD. The BRCA box plot shows higher C1orf185 RNA expression in normal versus tumor tissue (log2 FC = −0.125, t-test p < 0.001).
This table shows molecular features associated with C1orf185 in patient tissues and cancer cell lines. In patient samples, C1orf185 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf185 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and CNS.
